drugset / Trial / NCT03555149
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.
Timeline
- Start
- 2018-09-27
- Primary completion
- 2022-09-26
- Completion
- 2022-09-26
Outcome
Outcome not reported
Stopped (Enrollment): “The Sponsor made the decision to terminate the study due to start up and recruitment issues caused by limited resource availability at the treating centers.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Idasanutlin | Small molecule | — | Oral |
| Subject | Imprime PGG | Other / unclassified | — | Intravenous |
| Subject | Isatuximab | Monoclonal antibody | — | — |
| Subject | LOAd703 | Unknown | — | Other |
| Subject | Regorafenib | Small molecule | — | Oral |
| Subject | Selicrelumab | Monoclonal antibody | — | Subcutaneous |